Ironwood Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 3.62

IRWD Stock  USD 3.69  0.03  0.81%   
Ironwood Pharmaceuticals' future price is the expected price of Ironwood Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Ironwood Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Ironwood Pharmaceuticals Backtesting, Ironwood Pharmaceuticals Valuation, Ironwood Pharmaceuticals Correlation, Ironwood Pharmaceuticals Hype Analysis, Ironwood Pharmaceuticals Volatility, Ironwood Pharmaceuticals History as well as Ironwood Pharmaceuticals Performance.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
  
At present, Ironwood Pharmaceuticals' Price To Operating Cash Flows Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Cash Flow Ratio is expected to grow to 10.18, whereas Price Earnings Ratio is forecasted to decline to (1.86). Please specify Ironwood Pharmaceuticals' target price for which you would like Ironwood Pharmaceuticals odds to be computed.

Ironwood Pharmaceuticals Target Price Odds to finish over 3.62

The tendency of Ironwood Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 3.62  in 90 days
 3.69 90 days 3.62 
about 89.08
Based on a normal probability distribution, the odds of Ironwood Pharmaceuticals to stay above $ 3.62  in 90 days from now is about 89.08 (This Ironwood Pharmaceuticals probability density function shows the probability of Ironwood Stock to fall within a particular range of prices over 90 days) . Probability of Ironwood Pharmaceuticals price to stay between $ 3.62  and its current price of $3.69 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days the stock has the beta coefficient of 2.51 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Ironwood Pharmaceuticals will likely underperform. Additionally Ironwood Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Ironwood Pharmaceuticals Price Density   
       Price  

Predictive Modules for Ironwood Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ironwood Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ironwood Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.183.638.18
Details
Intrinsic
Valuation
LowRealHigh
2.296.8411.39
Details
Naive
Forecast
LowNextHigh
0.084.068.61
Details
6 Analysts
Consensus
LowTargetHigh
15.0216.5018.32
Details

Ironwood Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Ironwood Pharmaceuticals is not an exception. The market had few large corrections towards the Ironwood Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ironwood Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ironwood Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.35
β
Beta against Dow Jones2.51
σ
Overall volatility
0.39
Ir
Information ratio -0.04

Ironwood Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ironwood Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ironwood Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Ironwood Pharmaceuticals generated a negative expected return over the last 90 days
Ironwood Pharmaceuticals has high historical volatility and very poor performance
Ironwood Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Ironwood Pharmaceuticals, Inc. Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat

Ironwood Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ironwood Stock often depends not only on the future outlook of the current and potential Ironwood Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ironwood Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding155.4 M
Cash And Short Term Investments92.2 M

Ironwood Pharmaceuticals Technical Analysis

Ironwood Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Ironwood Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Ironwood Pharmaceuticals. In general, you should focus on analyzing Ironwood Stock price patterns and their correlations with different microeconomic environments and drivers.

Ironwood Pharmaceuticals Predictive Forecast Models

Ironwood Pharmaceuticals' time-series forecasting models is one of many Ironwood Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Ironwood Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Ironwood Pharmaceuticals

Checking the ongoing alerts about Ironwood Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Ironwood Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Ironwood Pharmaceuticals generated a negative expected return over the last 90 days
Ironwood Pharmaceuticals has high historical volatility and very poor performance
Ironwood Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Ironwood Pharmaceuticals, Inc. Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(0.01)
Revenue Per Share
2.393
Quarterly Revenue Growth
(0.20)
Return On Assets
0.1305
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.